Albendazole inhibits Pneumocystis carinii proliferation in inoculated immunosuppressed mice

M. S. Bartlett, T. D. Edlind, C. H. Lee, R. Dean, S. F. Queener, M. M. Shaw, J. W. Smith

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Albendazole, a benzimidazole derivative widely used for treating helminth infections, was successfully used to treat and prevent development of Pneumocystis carinii pneumonia in transtracheally inoculated immunosuppressed mice. For treatment, 3 weeks postinoculation, albendazole at 300 and 600 mg/kg of body weight per day was administered in food for 3 weeks. For prophylaxis, albendazole was begun on the same day as inoculation at 300 mg/kg/day for 7 days, and then the dose was reduced to 150 mg/kg/day for 35 additional days. With these regimens, albendazole was effective both for treatment and prophylaxis. Both dexamethasone-immunosuppressed and L3T4+ monoclonal antibody-immunosuppressed mouse models were used, and albendazole inhibited P. carinii infection in both.

Original languageEnglish (US)
Pages (from-to)1834-1837
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Volume38
Issue number8
DOIs
StatePublished - Jan 1 1994

Fingerprint

Pneumocystis carinii
Albendazole
Pneumocystis Infections
Pneumocystis Pneumonia
Helminths
Dexamethasone
Monoclonal Antibodies
Body Weight
Food
Infection

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Albendazole inhibits Pneumocystis carinii proliferation in inoculated immunosuppressed mice. / Bartlett, M. S.; Edlind, T. D.; Lee, C. H.; Dean, R.; Queener, S. F.; Shaw, M. M.; Smith, J. W.

In: Antimicrobial Agents and Chemotherapy, Vol. 38, No. 8, 01.01.1994, p. 1834-1837.

Research output: Contribution to journalArticle

Bartlett, M. S. ; Edlind, T. D. ; Lee, C. H. ; Dean, R. ; Queener, S. F. ; Shaw, M. M. ; Smith, J. W. / Albendazole inhibits Pneumocystis carinii proliferation in inoculated immunosuppressed mice. In: Antimicrobial Agents and Chemotherapy. 1994 ; Vol. 38, No. 8. pp. 1834-1837.
@article{7229f8b5564948cd9d619123e7021551,
title = "Albendazole inhibits Pneumocystis carinii proliferation in inoculated immunosuppressed mice",
abstract = "Albendazole, a benzimidazole derivative widely used for treating helminth infections, was successfully used to treat and prevent development of Pneumocystis carinii pneumonia in transtracheally inoculated immunosuppressed mice. For treatment, 3 weeks postinoculation, albendazole at 300 and 600 mg/kg of body weight per day was administered in food for 3 weeks. For prophylaxis, albendazole was begun on the same day as inoculation at 300 mg/kg/day for 7 days, and then the dose was reduced to 150 mg/kg/day for 35 additional days. With these regimens, albendazole was effective both for treatment and prophylaxis. Both dexamethasone-immunosuppressed and L3T4+ monoclonal antibody-immunosuppressed mouse models were used, and albendazole inhibited P. carinii infection in both.",
author = "Bartlett, {M. S.} and Edlind, {T. D.} and Lee, {C. H.} and R. Dean and Queener, {S. F.} and Shaw, {M. M.} and Smith, {J. W.}",
year = "1994",
month = "1",
day = "1",
doi = "10.1128/AAC.38.8.1834",
language = "English (US)",
volume = "38",
pages = "1834--1837",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "8",

}

TY - JOUR

T1 - Albendazole inhibits Pneumocystis carinii proliferation in inoculated immunosuppressed mice

AU - Bartlett, M. S.

AU - Edlind, T. D.

AU - Lee, C. H.

AU - Dean, R.

AU - Queener, S. F.

AU - Shaw, M. M.

AU - Smith, J. W.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Albendazole, a benzimidazole derivative widely used for treating helminth infections, was successfully used to treat and prevent development of Pneumocystis carinii pneumonia in transtracheally inoculated immunosuppressed mice. For treatment, 3 weeks postinoculation, albendazole at 300 and 600 mg/kg of body weight per day was administered in food for 3 weeks. For prophylaxis, albendazole was begun on the same day as inoculation at 300 mg/kg/day for 7 days, and then the dose was reduced to 150 mg/kg/day for 35 additional days. With these regimens, albendazole was effective both for treatment and prophylaxis. Both dexamethasone-immunosuppressed and L3T4+ monoclonal antibody-immunosuppressed mouse models were used, and albendazole inhibited P. carinii infection in both.

AB - Albendazole, a benzimidazole derivative widely used for treating helminth infections, was successfully used to treat and prevent development of Pneumocystis carinii pneumonia in transtracheally inoculated immunosuppressed mice. For treatment, 3 weeks postinoculation, albendazole at 300 and 600 mg/kg of body weight per day was administered in food for 3 weeks. For prophylaxis, albendazole was begun on the same day as inoculation at 300 mg/kg/day for 7 days, and then the dose was reduced to 150 mg/kg/day for 35 additional days. With these regimens, albendazole was effective both for treatment and prophylaxis. Both dexamethasone-immunosuppressed and L3T4+ monoclonal antibody-immunosuppressed mouse models were used, and albendazole inhibited P. carinii infection in both.

UR - http://www.scopus.com/inward/record.url?scp=0028061291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028061291&partnerID=8YFLogxK

U2 - 10.1128/AAC.38.8.1834

DO - 10.1128/AAC.38.8.1834

M3 - Article

C2 - 7986016

AN - SCOPUS:0028061291

VL - 38

SP - 1834

EP - 1837

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 8

ER -